Pulse Biosciences, Inc. (NASDAQ:PLSE) Director Robert W. Duggan Purchases 20,241 Shares

Pulse Biosciences, Inc. (NASDAQ:PLSE) Director Robert W. Duggan purchased 20,241 shares of the firm’s stock in a transaction on Friday, November 17th. The stock was bought at an average price of $6.10 per share, with a total value of $123,470.10. Following the acquisition, the director now owns 36,266,797 shares in the company, valued at $221,227,461.70. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Pulse Biosciences Price Performance

Shares of NASDAQ PLSE opened at $6.26 on Tuesday. The firm has a market capitalization of $344.24 million, a PE ratio of -6.80 and a beta of 1.25. Pulse Biosciences, Inc. has a 1-year low of $1.65 and a 1-year high of $9.69. The business’s fifty day moving average price is $4.51 and its two-hundred day moving average price is $5.98.

Hedge Funds Weigh In On Pulse Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of PLSE. Advisor Group Holdings Inc. raised its stake in shares of Pulse Biosciences by 25.5% in the 1st quarter. Advisor Group Holdings Inc. now owns 25,878 shares of the company’s stock valued at $126,000 after acquiring an additional 5,265 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Pulse Biosciences during the 1st quarter worth approximately $378,000. Bank of America Corp DE grew its holdings in shares of Pulse Biosciences by 5.1% during the 1st quarter. Bank of America Corp DE now owns 820,390 shares of the company’s stock worth $3,988,000 after purchasing an additional 39,645 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of Pulse Biosciences during the 2nd quarter worth approximately $184,000. Finally, Occudo Quantitative Strategies LP grew its holdings in shares of Pulse Biosciences by 217.3% during the 2nd quarter. Occudo Quantitative Strategies LP now owns 58,383 shares of the company’s stock worth $54,000 after purchasing an additional 39,981 shares in the last quarter. Institutional investors and hedge funds own 6.62% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a research note on Monday.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.